Insm : TTIP Container-Aktion - INSM / Stock analysis for insmed inc (insm:nasdaq gs) including stock price, stock chart, company news, key statistics, fundamentals and company profile.. Find the latest insmed, inc. Find the latest insmed, inc. Insm $25.17 $0.57 2.3% price as of june 1, 2021, 4:00 p.m. The high price target for insm is $60.00 and the low price target for insm is $44.00. Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases.
Insm stock was sold by a variety of institutional investors in the last quarter, including citigroup inc., russell investments group ltd., goldman sachs group inc., palo alto investors lp, artisan partners limited partnership, millennium management llc, samlyn capital llc, and first light asset management llc. Insmed incorporated (nasdaq:insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement. There are currently 7 buy ratings for the stock, resulting in a consensus rating of buy. today Insmed (insm) starts dosing in phase iii bronchiectasis study. The high price target for insm is $60.00 and the low price target for insm is $44.00.
Get the latest insmed, inc. Top 10 healthcare stocks to buy for the future. Insmed incorporated nasdaq updated jun 7, 2021 9:24 pm. Share your opinion and gain insight from other stock traders and investors. Insm investment & stock information. Find the latest on short interest for insmed, inc. Let's start up with the current stock price of insmed incorporated (insm), which is $25.99 to be very precise. Et in a corporate presentation
Insmed incorporated (nasdaq:insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement.
Insm investment & stock information. Insmed incorporated (nasdaq:insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement. Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed announces initiation of phase 3 aspen study of brensocatib in patients with bronchiectasis. Common stock (insm) at nasdaq.com. Get the latest insmed stock price and detailed information including insm news, historical charts and realtime prices. (insm) stock discussion in yahoo finance's forum. View the latest insm financial statements, income statements and financial ratios. Insm $25.17 $0.57 2.3% price as of june 1, 2021, 4:00 p.m. Insmed (insm) starts dosing in phase iii bronchiectasis study. We are powered by purpose, with an active promise to join your fight. Share your opinion and gain insight from other stock traders and investors. Insmed (nasdaq:insm) is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases.
Insmed (insm) starts dosing in phase iii bronchiectasis study. Et view interactive insm charts Stock analysis for insmed inc (insm:nasdaq gs) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Insm investment & stock information. Find the latest on short interest for insmed, inc.
Common stock (insm) at nasdaq.com. Our strong and experienced management team embodies our culture, setting the tone for an organization that acts boldly, thinks creatively, and puts patients first in everything we do. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Find the latest on short interest for insmed, inc. Get the latest insmed, inc. Let's start up with the current stock price of insmed incorporated (insm), which is $25.99 to be very precise. We are powered by purpose, with an active promise to join your fight.
Insm investment & stock information.
Et in a corporate presentation Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The stock rose vividly during the last session to $28.50 after opening rate of $28.215 while the lowest price it went was recorded $24.89 before closing at $32.58. The high price target for insm is $60.00 and the low price target for insm is $44.00. The company report on may 10, 2021 that insmed announces proposed concurrent public offerings of common stock and convertible senior notes due 2028. Get the latest insmed, inc. Security date/time rebate rate fee rate shares available; Insm stock was sold by a variety of institutional investors in the last quarter, including citigroup inc., russell investments group ltd., goldman sachs group inc., palo alto investors lp, artisan partners limited partnership, millennium management llc, samlyn capital llc, and first light asset management llc. Insmed (nasdaq:insm) is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Annual stock financials by marketwatch. Find the latest insmed, inc. Top 10 healthcare stocks to buy for the future.
Common stock (insm) at nasdaq.com. The high price target for insm is $60.00 and the low price target for insm is $44.00. Share your opinion and gain insight from other stock traders and investors. Bridgewater, n.j., may 19, 2021 insmed incorporated (insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported data from a total of nine posters and oral presentations across its three programs—arikayce, brensocatib, and treprostinil palmitil inhalation powder—at. Insm $25.17 $0.57 2.3% price as of june 1, 2021, 4:00 p.m.
Insmed incorporated (nasdaq:insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement. The jefferies virtual healthcare conference on june 1, 2021 at 9:00 a.m. Insmed (insm) starts dosing in phase iii bronchiectasis study. (nasdaq:insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following virtual investor events: (insm) stock quote, history, news and other vital information to help you with your stock trading and investing. We are powered by purpose, with an active promise to join your fight. Get the latest insmed stock price and detailed information including insm news, historical charts and realtime prices. Insm investment & stock information.
Stock analysis for insmed inc (insm:nasdaq gs) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
The company report on may 10, 2021 that insmed announces proposed concurrent public offerings of common stock and convertible senior notes due 2028. Et in a corporate presentation Our strong and experienced management team embodies our culture, setting the tone for an organization that acts boldly, thinks creatively, and puts patients first in everything we do. Find the latest insmed, inc. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Top 10 healthcare stocks to buy for the future. Get the latest insmed, inc. Let's start up with the current stock price of insmed incorporated (insm), which is $25.99 to be very precise. Insmed incorporated (nasdaq:insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement. Insm investment & stock information. Insm | complete insmed inc. Insmed incorporated nasdaq updated jun 7, 2021 9:24 pm. (insm) stock quote, history, news and other vital information to help you with your stock trading and investing.